NCT07017270View on ClinicalTrials.gov

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

September 30, 2027

Conditions
Kidney Disease, ChronicDiabetesDialysisEnd Stage Kidney Disease (ESRD)
Interventions
DRUG

Semaglutide Pen

Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.

Trial Locations (1)

M5B1W8

Unity Health Toronto, Toronto

All Listed Sponsors
lead

Unity Health Toronto

OTHER